A double-blind, multicenter, placebo controlled, acute and extension study of 2 doses of MK-0869 [aprepitant] in the treatment of patients with major depressive disorder

Trial Profile

A double-blind, multicenter, placebo controlled, acute and extension study of 2 doses of MK-0869 [aprepitant] in the treatment of patients with major depressive disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top